2.2. Intervention and Its Control
CVD, HEART, SECONDARY
Participants were randomized to receive n−3 fatty acids, vitamin D, both active agents, or both placebos between November 2011 and March 2014. Participants assigned to the n−3 fatty acid supplementation group were provided with a daily dose of 1 g of n−3 fatty acids, administered in the form of a fish-oil capsule. The fish-oil capsules contained 840 mg of n−3 fatty acids, including 460 mg of eicosatetraenoic acids (EPA) and 380 mg of docosahexaenoic acids (DHA). The dose of n−3 fatty acids chosen was based on the one recommended by the American Heart Association for CVD protection and reported to be beneficial in a secondary prevention population [